EICHOR
● Terminated
Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients
Condition: Sepsis, Severe · Sponsor: Revimmune
About this study
This phase II randomized study will assess the effect of receiving IV recombinant human IL-7 (CYT107) versus placebo in lymphopenic sepsis patients The aim is to confirm the immune cell reconstitution observed in other studies and other patient populations among which the IRIS-7 A\&B study which was conducted in the same patient population.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (10)
| University of Florida | Gainesville, Florida, United States | — |
| Washington University School of Medicine | St Louis, Missouri, United States | — |
| CHU Angers | Angers, France | — |
| Hopital HENRI MONDOR | Créteil, France | — |
| CHU Dijon Bourgogne | Dijon, France | — |
| University Hospital of Limoges | Limoges, France | — |
| Hôpital Edouard Herriot | Lyon, France | — |
| Chr Orleans | Orléans, France | — |
| Hopital COCHIN | Paris, France | — |
| Chru Bretonneau | Tours, France | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03821038